<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8">
    <title>Commonly Used HIV Drugs</title>
    <link rel="stylesheet" href="/genralPages.css">
    <script src="/script.js"></script>
    <script src="https://kit.fontawesome.com/834304401a.js" crossorigin="anonymous"></script>
    <style>
      body {
        font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;
        font-size: 16px;
        font-weight: bold;
        line-height: 2;
        color: #333;
        background-image: url("/images/medications.png");
        background-size: cover;
        background-repeat: no-repeat;
        background-position: center;
      }
      table {
        border-collapse: collapse;
        width: 100%;
      }
      th, td {
        text-align: left;
        padding: 8px;
      }
      th {
        background-color: #4CAF50;
        color: white;
      }
      tr:nth-child(even) {
        background-color: #f2f2f2;
      }
      input[type="text"] {
        width: 100%;
        padding: 12px 20px;
        margin: 8px 0;
        box-sizing: border-box;
        border: 2px solid #ccc;
        border-radius: 4px;
      }
      input[type="text"]:focus {
        border: 2px solid #4CAF50;
      }
      .section {
        margin-top: 20px;
      }
      .section h2 {
        margin-bottom: 10px;
      }
      .small-note {
        font-size: 0.9rem;
        font-weight: normal;
      }
      ul {
        margin-left: 20px;
      }
    </style>
  </head>
  <body>
    <header>
      <nav class="logo-container">
        <div class="logo-container">
          <h1 class="main-header">Commonly Used HIV Drugs</h1>
          <div class="navbar-icons">
            <a href="/index.html" title="Home"><i class="fa-solid fa-house" alt="House icon"></i></a>
          </div>
          <button class="back-button" onclick="goBack()">Back</button>
        </div>
      </nav>
    </header>

    <main>
      <p class="small-note">
        <strong>Note:</strong> Doses below are typical adult maintenance doses. Initiation, switching or interruption of ART
        should follow your hospital / HIV clinic guidelines and be discussed with a senior or HIV specialist.
      </p>

      <input type="text" id="search" onkeyup="searchTable()" placeholder="Search for drugs...">

      <table id="hiv">
        <tr>
          <th>Drug</th>
          <th>Typical Adult Dose</th>
          <th>Route</th>
          <th>Indication (Summary)</th>
        </tr>
        <tr>
          <td>Tenofovir disoproxil fumarate (TDF)</td>
          <td>300 mg once daily</td>
          <td>Oral</td>
          <td>Backbone NRTI in ART; used in HIV-1 treatment and some PrEP regimens</td>
        </tr>
        <tr>
          <td>Emtricitabine (FTC)</td>
          <td>200 mg once daily</td>
          <td>Oral</td>
          <td>NRTI; combined with TDF in HIV-1 treatment and PrEP regimens</td>
        </tr>
        <tr>
          <td>Dolutegravir (DTG)</td>
          <td>50 mg once daily</td>
          <td>Oral</td>
          <td>Integrase inhibitor; core agent in many first-line regimens</td>
        </tr>
        <tr>
          <td>Raltegravir (RAL)</td>
          <td>400 mg twice daily</td>
          <td>Oral</td>
          <td>Integrase inhibitor; used in ART and sometimes PEP</td>
        </tr>
        <tr>
          <td>Atazanavir (ATV)</td>
          <td>300–400 mg once daily with ritonavir 100 mg once daily (or 200 mg if given with TDF)</td>
          <td>Oral</td>
          <td>Protease inhibitor (usually boosted); component of some ART regimens</td>
        </tr>
        <tr>
          <td>Ritonavir (RTV)</td>
          <td>100 mg once or twice daily (boosting dose)</td>
          <td>Oral</td>
          <td>Pharmacokinetic booster for protease inhibitors</td>
        </tr>
        <tr>
          <td>Darunavir (DRV)</td>
          <td>800 mg once daily + RTV 100 mg once daily, or 600 mg BD + RTV 100 mg BD</td>
          <td>Oral</td>
          <td>Boosted protease inhibitor for ART, especially in treatment-experienced patients</td>
        </tr>
        <tr>
          <td>Lopinavir/ritonavir (LPV/r)</td>
          <td>800/200 mg once or twice daily</td>
          <td>Oral</td>
          <td>Boosted protease inhibitor combination for ART</td>
        </tr>
      </table>

      <div class="section">
        <h2>Emergency Department Tips</h2>
        <ul>
          <li>
            <strong>Do not start or stop chronic ART lightly:</strong> Avoid changing long-term regimens from the ED
            unless clear toxicity or life-threatening reaction is suspected and a senior / HIV specialist is involved.
          </li>
          <li>
            <strong>Post-Exposure Prophylaxis (PEP):</strong> Use your local PEP guideline for occupational and sexual exposures.
            Start as soon as possible (ideally within hours, and usually within 72 hours) and ensure good follow-up.
          </li>
          <li>
            <strong>Pre-Exposure Prophylaxis (PrEP):</strong> Initial counselling and prescriptions should usually be done
            via HIV / primary care clinics; the ED role is often identifying candidates and referring appropriately.
          </li>
          <li>
            <strong>Drug interactions:</strong> Always consider interactions with TB drugs, anticonvulsants, azoles,
            anticoagulants and anti-arrhythmics – especially with boosted protease inhibitors (RTV / LPV/r / DRV).
          </li>
          <li>
            <strong>Acute presentations:</strong> In suspected IRIS, severe opportunistic infection, liver failure or lactic acidosis,
            urgently discuss with an HIV / ID specialist before stopping or changing ART.
          </li>
          <li>
            <strong>Adherence questions:</strong> Ask about missed doses, stock-outs and traditional / over-the-counter medicines.
          </li>
        </ul>
      </div>

      <div class="section">
        <h2>Common Side Effects & Cautions (Quick Reference)</h2>
        <table>
          <tr>
            <th>Drug</th>
            <th>Common Side Effects</th>
            <th>Key Cautions</th>
          </tr>
          <tr>
            <td>TDF</td>
            <td>Renal dysfunction, ↓ bone mineral density, mild GI upset</td>
            <td>
              Avoid or reduce dose in significant renal impairment; monitor creatinine and eGFR.
            </td>
          </tr>
          <tr>
            <td>FTC</td>
            <td>Generally well tolerated; headache, nausea</td>
            <td>
              Adjust dose in renal impairment; usually given in fixed-dose combination with TDF.
            </td>
          </tr>
          <tr>
            <td>DTG</td>
            <td>Insomnia, headache, GI upset, weight gain</td>
            <td>
              Watch for interactions with cation-containing antacids; discuss with specialist in early pregnancy or women of child-bearing potential as per local guidance.
            </td>
          </tr>
          <tr>
            <td>RAL</td>
            <td>Headache, nausea, rash, rare myopathy</td>
            <td>
              CK elevation possible; separate from polyvalent cation antacids.
            </td>
          </tr>
          <tr>
            <td>ATV</td>
            <td>Hyperbilirubinaemia (jaundice), GI upset</td>
            <td>
              Avoid with proton pump inhibitors in some regimens; check for drug interactions; use with RTV as booster.
            </td>
          </tr>
          <tr>
            <td>DRV + RTV</td>
            <td>GI upset, rash, ↑ lipids, liver enzyme elevation</td>
            <td>
              Many drug interactions (CYP3A4); caution in hepatic impairment; always confirm doses with guideline / senior.
            </td>
          </tr>
          <tr>
            <td>LPV/r</td>
            <td>GI upset, hyperlipidaemia, hyperglycaemia</td>
            <td>
              Risk of QT / PR prolongation and metabolic complications; check interactions with other QT-prolonging drugs.
            </td>
          </tr>
        </table>
        <p class="small-note">
          <strong>Reminder:</strong> Management of ART, PEP and PrEP must follow national / provincial HIV guidelines. When unsure,
          stabilise the patient and contact your local HIV / ID team or senior doctor for advice.
        </p>
      </div>
    </main>

    <script>
      function searchTable() {
        let input, filter, table, tr, td, i, txtValue;
        input = document.getElementById("search");
        filter = input.value.toUpperCase();
        table = document.getElementById("hiv");
        tr = table.getElementsByTagName("tr");
        for (i = 1; i < tr.length; i++) {
          td = tr[i].getElementsByTagName("td")[0];
          if (td) {
            txtValue = td.textContent || td.innerText;
            if (txtValue.toUpperCase().indexOf(filter) > -1) {
              tr[i].style.display = "";
            } else {
              tr[i].style.display = "none";
            }
          }
        }
      }
    </script>
  </body>
</html>
